Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros










Intervalo de ano de publicação
1.
Asian Journal of Andrology ; (6): 179-183, 2023.
Artigo em Inglês | WPRIM (Pacífico Ocidental) | ID: wpr-971024

RESUMO

Management and treatment of terminal metastatic castration-resistant prostate cancer (mCRPC) remains heavily debated. We sought to investigate the efficacy of programmed cell death 1 (PD-1) inhibitor plus anlotinib as a potential solution for terminal mCRPC and further evaluate the association of genomic characteristics with efficacy outcomes. We conducted a retrospective real-world study of 25 mCRPC patients who received PD-1 inhibitor plus anlotinib after the progression to standard treatments. The clinical information was extracted from the electronic medical records and 22 patients had targeted circulating tumor DNA (ctDNA) next-generation sequencing. Statistical analysis showed that 6 (24.0%) patients experienced prostate-specific antigen (PSA) response and 11 (44.0%) patients experienced PSA reduction. The relationship between ctDNA findings and outcomes was also analyzed. DNA-damage repair (DDR) pathways and homologous recombination repair (HRR) pathway defects indicated a comparatively longer PSA-progression-free survival (PSA-PFS; 2.5 months vs 1.2 months, P = 0.027; 3.3 months vs 1.2 months, P = 0.017; respectively). This study introduces the PD-1 inhibitor plus anlotinib as a late-line therapeutic strategy for terminal mCRPC. PD-1 inhibitor plus anlotinib may be a new treatment choice for terminal mCRPC patients with DDR or HRR pathway defects and requires further investigation.


Assuntos
Masculino , Humanos , Antígeno Prostático Específico , Resultado do Tratamento , Neoplasias de Próstata Resistentes à Castração/tratamento farmacológico , Inibidores de Checkpoint Imunológico/uso terapêutico , Estudos Retrospectivos
2.
Chinese Journal of Stomatology ; (12): 347-351, 2008.
Artigo em Chinês | WPRIM (Pacífico Ocidental) | ID: wpr-235904

RESUMO

<p><b>OBJECTIVE</b>To investigate the effect of putative periodontopathogenic bacteria on the development of drug-induced gingival overgrowth (GO) in renal transplant recipients.</p><p><b>METHODS</b>A total of 57 patients undergoing cyclosporine treatment were divided into two groups according to GO index: with gingival overgrowth (group A) and without gingival overgrowth (group B). Demographic, pharmacologic and periodontal data were analyzed. The real-time polymerase chain reaction (PCR) method was used to detect and quantify five putative periodontopathogenic bacteria, including Porphyromonas gingivalis (Pg), Actinobacillus actinomycetemcomitans (Aa), Prevotella intermedia (Pi), Treponema denticola (Td) and Tannerella forsythia (Tf) in subgingival samples. Moreover, the relationship between the bacterial amount and the severity of GO was analyzed.</p><p><b>RESULTS</b>Group A presented a significantly higher plaque index, sulcus bleeding index and probing depth than group B (P < 0.01). The occurrences of Pg, Td, and Tf in the group A (96%, 82% and 89%) were significantly increased compared with those in the group B (69%, 55% and 66%, P < 0. 05), respectively. The prevalence of Pg, Td, and Tf in the group A (79%) was markedly higher than that in the group B (38%, P < 0.01). The bacterial amount of Pg, Td, Tf and Pi were enhanced along with the severity of GO. However, the bacterial amount of Aa had no difference between two groups.</p><p><b>CONCLUSIONS</b>Pg, Td, and Tf may have a significant relationship with the development of GO.</p>


Assuntos
Adulto , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Aggregatibacter actinomycetemcomitans , Técnicas de Tipagem Bacteriana , Ciclosporina , DNA Bacteriano , Crescimento Excessivo da Gengiva , Microbiologia , Transplante de Rim , Reação em Cadeia da Polimerase , Métodos , Porphyromonas gingivalis , Prevotella intermedia , Treponema denticola
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...